Contrasting of Akebia Therapeutics Inc. (AKBA) and Unity Biotechnology Inc. (NASDAQ:UBX)

Akebia Therapeutics Inc. (NASDAQ:AKBA) and Unity Biotechnology Inc. (NASDAQ:UBX) compete with each other in the Biotechnology sector. We will analyze and compare their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Akebia Therapeutics Inc. 234.48M 2.06 192.59M -2.40 0.00
Unity Biotechnology Inc. N/A 0.00 79.03M -6.43 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Akebia Therapeutics Inc. and Unity Biotechnology Inc.

Profitability

Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Akebia Therapeutics Inc. -82.13% -23.8% -12.1%
Unity Biotechnology Inc. 0.00% -46.4% -42.4%

Liquidity

1.8 and 1.3 are the respective Current Ratio and a Quick Ratio of Akebia Therapeutics Inc. Its rival Unity Biotechnology Inc.’s Current and Quick Ratios are 13.7 and 13.7 respectively. Unity Biotechnology Inc. has a better chance of clearing its pay short and long-term debts than Akebia Therapeutics Inc.

Analyst Ratings

Akebia Therapeutics Inc. and Unity Biotechnology Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Akebia Therapeutics Inc. 0 1 2 2.67
Unity Biotechnology Inc. 0 0 1 3.00

Akebia Therapeutics Inc.’s upside potential is 282.20% at a $15.67 consensus target price. Meanwhile, Unity Biotechnology Inc.’s consensus target price is $21, while its potential upside is 140.55%. Based on the analysts belief we can conclude, Akebia Therapeutics Inc. is looking more favorable than Unity Biotechnology Inc.

Institutional & Insider Ownership

Akebia Therapeutics Inc. and Unity Biotechnology Inc. has shares owned by institutional investors as follows: 69.7% and 72.3%. Insiders owned 1.1% of Akebia Therapeutics Inc. shares. On the other hand, insiders owned about 12.22% of Unity Biotechnology Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Akebia Therapeutics Inc. -1.7% -17.52% -10.23% -35.38% -44.49% 4.7%
Unity Biotechnology Inc. 6.65% 22.53% -18.71% -21.98% -37.12% -42.8%

For the past year Akebia Therapeutics Inc. had bullish trend while Unity Biotechnology Inc. had bearish trend.

Summary

Akebia Therapeutics Inc. beats on 7 of the 11 factors Unity Biotechnology Inc.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, Europe, China, and internationally, as well as with Mitsubishi Tanabe Pharma Corporation for the development and commercialization to vadadustat in Japan and other Asian countries. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.